3M Cavilon Advanced Skin Protectant for the Prophylaxis of Radiation Dermatitis


About this study

This study observes a liquid skin protectant that is a polymeric-cyanoacrylate solution designed to protect intact or damaged skin due to radiation.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18years.
  • Patient has initial or recurrent disease
  • Undergoing external beam radiotherapy at the Mayo Clinic Rochester campus Note: Patients who are undergoing concurrent chemotherapy are eligible
  • Ability to complete questionnaire(s) by themselves or with assistance
  • Provide informed written consent
  • Willing to consent for photography of radiation field
  • Available to return to Mayo Clinic in within 1 week post treatment for assessment (+/- 7 days).
  • At risk for developing ≥ grade 2 dermatitis radiation as determined by treating Radiation Oncology clinician
  • Biologic effective dose of >42 Gy10 as calculated using the web site EQD2.com.

Exclusion Criteria:

  • Unable to provide informed consent
  • Patients with active rash, pre-existing dermatitis, lupus or scleroderma within the treatment area that may make skin assessment for the study difficult
  • Known history of developing an allergic reaction after using a product containing cyanoacrylate or acrylates
  • Subject has a medical condition that in the opinion of the investigator should exclude him/her from participating in the study
  • Subject has been enrolled in an investigational study where product was applied to the proposed study site within 30 days of the screening visit
  • The skin area affected by radiation requires treatment with a concomitant medication or product (if applicable)

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Ivy Petersen, M.D.

Closed for enrollment

More information


Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions